Lv11
40 积分 2022-05-13 加入
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
1小时前
求助中
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1小时前
已完结
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
3天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
7天前
已完结
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
11天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
20天前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
21天前
已完结
Targeted Therapy for Colorectal Cancer
24天前
已关闭
Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3
1个月前
已完结
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
1个月前
已完结
皖公网安备34019202002308
